Back to Results

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax-AXL-ADC) in patients with solid tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Erin Schenk,  MD, PhD

Erin Schenk, MD, PhD

Study ID

Protocol Number: 17-2451

ClinicalTrials.gov: NCT02988817

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers